Emerging Epigenetic Targets and Therapies in Cancer Medicine | Zendy

Relja Popovic | Zendy; Jonathan D. Licht | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Emerging Epigenetic Targets and Therapies in Cancer Medicine

Author(s) -

Relja Popovic,

Jonathan D. Licht

Publication year - 2012

Publication title -

cancer discovery

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 6.795

H-Index - 163

eISSN - 2159-8290

pISSN - 2159-8274

DOI - 10.1158/2159-8290.cd-12-0076

Subject(s) - epigenetics , histone deacetylase , epigenetic therapy , methyltransferase , biology , chromatin , cancer epigenetics , histone , dna methyltransferase , dna methylation , epigenetic regulation of neurogenesis , chromatin remodeling , computational biology , histone methyltransferase , cancer research , bioinformatics , genetics , gene expression , dna , gene , methylation

Abnormalities in the epigenetic regulation of chromatin structure and function can lead to aberrant gene expression and cancer development. Consequently, epigenetic therapies aim to restore normal chromatin modification patterns through the inhibition of various components of the epigenetic machinery. Histone deacetylase and DNA methyltransferase inhibitors represent the first putative epigenetic therapies; however, these agents have pleiotropic effects and it remains unclear how they lead to therapeutic responses. More recently, drugs that inhibit histone methyltransferases were developed, perhaps representing more specific agents. We review emerging epigenetic targets in cancer and present recent models of promising epigenetic therapies.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research